Synthesis of [1,2-a]-fused tricyclic dihydroquinolines by palladium-catalyzed intramolecular C–N cross-coupling of polarized heterocyclic enamines
作者:Břetislav Brož、Zdeňka Růžičková、Petr Šimůnek
DOI:10.3998/ark.5550190.p009.723
日期:——
A simple methodology for [1,2-a]-fusedtricyclicdihydroquinolines is established. The key step of the methodology is an intramolecular Buchwald-Hartwig amination reaction of suitable halogenated (both bromo and chloro) cyclic enaminoketones, enaminoesters and enaminonitriles with various ring size (from fiveto seven-membered). Optimal reaction conditions (palladium source, base, ligand) depend on
[EN] BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 1,4-DIHYDROPYRIDINE SUBSTITUÉS PAR INDAZOLE BI- ET TRICYCLIQUES ET LEURS UTILISATIONS
申请人:BAYER SCHERING PHARMA AG
公开号:WO2010094405A1
公开(公告)日:2010-08-26
This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS
申请人:Adler Marc
公开号:US20080176833A1
公开(公告)日:2008-07-24
This invention provides novel dihydropyridine derivatives of the formula I
having protein tyrosine kinase inhibitory activity, to process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions.
BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF
申请人:Michels Martin
公开号:US20120035409A1
公开(公告)日:2012-02-09
This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.